Cargando…
Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond
Uveal melanoma (UM) is the most common ocular malignancy in adults, associated with the poorest prognosis, with metastatic disease occurring in up to 50% of patients. In contrast to metastatic cutaneous melanoma, the use of immune checkpoint inhibitors is associated with poor outcomes in metastatic...
Autores principales: | Gerard, C., Shum, B., Nathan, P., Turajlic, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362360/ https://www.ncbi.nlm.nih.gov/pubmed/37483658 http://dx.doi.org/10.1016/j.iotech.2023.100386 |
Ejemplares similares
-
Tebentafusp: a first-in-class treatment for metastatic uveal
melanoma
por: Howlett, Sarah, et al.
Publicado: (2023) -
Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma
por: Damato, Bertil E., et al.
Publicado: (2019) -
Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations
por: Montazeri, Kamaneh, et al.
Publicado: (2023) -
Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma
por: Hua, Gwen, et al.
Publicado: (2022) -
Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study
por: Tomsitz, Dirk, et al.
Publicado: (2023)